Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study by Nordestgaard Børge G, Kontula Kimmo, Benn Marianne, Dahlöf Björn, de Faire Ulf, Edelman Jonathan M, Eliasson Erik, Fyhrquist Frej, Hille Darcy A, Ibsen Hans, Lyle Paulette A, Berg Kåre, Sandberg Mia, Sethi Amar A, Wong Peggy H, Os Ingrid in Pharmacogenetics and genomics (2010). PubMed

Abstract

This pharmacogenetics substudy from the Losartan Intervention for Endpoint reduction in Hypertension study in patients with hypertension and left ventricular hypertrophy (LVH) treated with the angiotensin receptor blocker losartan versus the beta-blocker atenolol for 4.8 years tested whether the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene and 12 other previously well-characterized polymorphisms of hypertension susceptibility genes affected blood pressure reduction, heart rate reduction, cardiovascular events, and/or response to treatment. These polymorphisms were chosen because they could affect blood pressure control or the pharmacological action of losartan or atenolol.

[ hide abstract ]

Discussed In Paper